GPT
EstablishedGPT/ALT is a liver-specific enzyme marker, central to MASLD/MASH diagnosis under the 2023-renamed disease framework.
ALT is a liver enzyme test whose disease name recently changed — "fatty liver disease" is now officially called MASLD to better reflect its connection to metabolic health. Also worth knowing: many people with a lab-"normal" ALT may still have relevant liver fat buildup, since typical lab reference ranges run higher than what's truly healthy.
GPT (glutamate pyruvate transaminase) is the gene symbol for alanine aminotransferase (ALT), a liver enzyme more specific to hepatocellular injury than AST since it is found predominantly in the liver rather than multiple tissues.
Elevated ALT is a sensitive marker of liver cell injury, commonly from viral hepatitis, alcohol use, medications, or metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called NAFLD).
In June 2023, NAFLD was formally renamed MASLD (metabolic dysfunction-associated steatotic liver disease) by a multi-society consensus, specifically to remove stigmatizing language and tie the diagnosis to actual metabolic risk factors rather than just excluding alcohol; this is now the current terminology across AASLD/EASL guidelines. Standard lab-reported "normal" ALT ranges are also higher than what's actually normal for liver health — true normal is lower (29-33 U/L in men, 19-25 U/L in women per AASLD).
ALT is used both diagnostically and as a monitoring biomarker for treatment response in pediatric and adult fatty liver disease trials; persistently elevated ALT despite lifestyle intervention may prompt escalation to pharmacologic MASLD/MASH therapy or further fibrosis workup via FIB-4.
The June 2023 NAFLD-to-MASLD nomenclature change reflects a major, current shift in how fatty liver disease is classified.
- AASLD. (2023). Steatotic-What? Changes in Fatty Liver Nomenclature.
- PMC. (2023). Precipitous changes in nomenclature and definitions—NAFLD becomes SLD.